Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in epidermal growth factor receptor-2-negative, mesenchymal-epithelial transition-positive gastroesophageal adenocarcinoma: is it a real failure?

Literature DB >> 30363693

Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in epidermal growth factor receptor-2-negative, mesenchymal-epithelial transition-positive gastroesophageal adenocarcinoma: is it a real failure?

Jimmy T Efird¹, Charulata Jindal¹, Timothy Fitzgerald², Tithi Biswas³.

Abstract

Entities: Chemical

Year: 2018 PMID： 30363693 PMCID： PMC6182040 DOI： 10.21037/tgh.2018.08.06

Source DB: PubMed Journal: Transl Gastroenterol Hepatol ISSN： 2415-1289

Keyword Cloud
References

× No keyword cloud information.

25 in total

1. A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.

Authors: Manish A Shah; Jae-Yong Cho; Iain B Tan; Niall C Tebbutt; Chia-Jui Yen; Alice Kang; David S Shames; Lilian Bu; Yoon-Koo Kang
Journal: Oncologist Date: 2016-07-08

Review 2. Helicobacter pylori and gastric cancer: factors that modulate disease risk.

Authors: Lydia E Wroblewski; Richard M Peek; Keith T Wilson
Journal: Clin Microbiol Rev Date: 2010-10 Impact factor: 26.132

3. Cancer Statistics, 2017.

Authors: Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal: CA Cancer J Clin Date: 2017-01-05 Impact factor: 508.702

4. Expression of c-Met and hepatocyte growth factor in various gastric pathologies and its association with Helicobacter pylori infection.

Authors: Chuan Xie; Zhen Yang; Yi Hu; Ximei Cao; Jiang Chen; Yin Zhu; Nonghua Lu
Journal: Oncol Lett Date: 2017-09-18 Impact factor: 2.967

Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in epidermal growth factor receptor-2-negative, mesenchymal-epithelial transition-positive gastroesophageal adenocarcinoma: is it a real failure?

1. A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.

Review 2. Helicobacter pylori and gastric cancer: factors that modulate disease risk.

3. Cancer Statistics, 2017.

4. Expression of c-Met and hepatocyte growth factor in various gastric pathologies and its association with Helicobacter pylori infection.

5. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients.

Review 6. Clinical significance of MET in gastric cancer.

7. Blocked randomization with randomly selected block sizes.

Review 8. Helicobacter pylori and gastric cancer: a state of the art review.

9. MET4 expression predicts poor prognosis of gastric cancers with Helicobacter pylori infection.

Review 10. Helicobacter pylori Diversity and Gastric Cancer Risk.